Publications by authors named "J Sanchez-de-Toledo"
Background: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD).
View Article and Find Full Text PDFArticle Synopsis
- Rhabdomyosarcoma (RMS) treatment has improved, but high-risk patients still struggle with poor survival rates due to issues like PAX3/7-FOXO1 fusion proteins that cause metastasis and resistance to therapy.
- This study focused on TRIB3, a regulator of FOXO1, finding that higher TRIB3 expression in RMS tumors correlates with the fusion protein's presence and contributes to cell proliferation.
- Genetic inhibition of TRIB3 not only reduced PAX3-FOXO1 levels and affected signaling pathways but also delayed tumor growth and improved survival rates in vivo, indicating TRIB3 could be a promising therapeutic target for aggressive RMS.
Introduction: At present, neurodevelopmental abnormalities are the most frequent type of complication in school-aged children with congenital heart disease (CHD). We analysed the incidence of acute neurologic events (ANEs) in patients with operated CHD and the usefulness of neuromarkers for the prediction of neurodevelopment outcomes.
Methods: Prospective observational study in infants with a prenatal diagnosis of CHD who underwent cardiac surgery in the first year of life.